36052-27-4

Usage

Uses

Used in Organic Synthesis:
3-Aminopyridine-2-carboxylic acid methyl ester is used as an organic synthesis intermediate for the preparation of a wide range of chemical compounds. Its amino and ester groups make it a valuable building block for the development of new molecules with diverse properties and applications.
Used in Pharmaceutical Industry:
3-Aminopyridine-2-carboxylic acid methyl ester is used as a pharmaceutical intermediate, playing a crucial role in the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of novel pharmaceutical compounds with potential applications in various medical fields.
Used in Laboratory Research and Development:
3-Aminopyridine-2-carboxylic acid methyl ester is utilized in laboratory research and development processes, where it is employed to study its chemical properties, reactivity, and potential applications in the synthesis of new compounds. This research contributes to the advancement of chemical and pharmaceutical sciences.
Used in Chemical Production Processes:
3-Aminopyridine-2-carboxylic acid methyl ester is also used in chemical production processes, where it serves as a key intermediate in the manufacturing of various chemical products. Its versatility and reactivity make it an essential component in the production of a range of chemicals with different applications.

Synthesis

To a solution of 3-aminopyridine-2-carboxylic acid (20 g, 144.9 mmol) in methanol (300 mL) was added conc. sulfuric acid (5.4 mL), and the mixture was heated under reflux for 5 days. The reaction mixture was concentrated under reduced pressure, water was added thereto, and sodium carbonate was added thereto until the complete of foaming. The mixture was extracted with dichloromethane (x3), the organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give methyl 3-aminopyridine-2-carboxylate (17.0 g, 77%) as a pale yellow solid. 1H-NMR(300MHz,CDCl3):δ3.95(3H,s),5.72(2H,brs),7.03(1H,dd,J=0.99,8. 35Hz),7.18-7.21(1H,m),8.05(1H,dd,J=0.96,4.04Hz).

InChI:InChI=1/C7H8N2O2/c1-11-7(10)6-5(8)3-2-4-9-6/h2-4H,8H2,1H3

Upstream product

• 1462-86-8 3-amino-pyridine-2-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 186581-53-3 diazomethane 
• 912369-42-7 methyl 3-{[(tert-butoxy)carbonyl]amino}pyridine-2-carboxylate 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 
• 4664-00-0 2,3-pyridinedicarboximide 

Downstream Products

• 400722-89-6 methyl 3-benzoylaminopicolinate 
• 400722-90-9 methyl 3-p-nitrobenzoylaminopicolinate 
• 181123-14-8 methyl 3-amido-(N-phenylacetyl)picolinate 
• 371947-78-3 methyl 3-[(3-methoxybenzoyl)amino]pyridine-2-carboxylate 
• 400722-92-1 methyl 3-benzoylaminopicolinate N-oxide 
• 181122-95-2 5-aza-4-hydroxy-3-phenylquinolin-2-one 
• 400722-93-2 methyl 3-nitrobenzoylaminopicolinate N-oxide 
• 1225208-03-6 4-Hydroxy-3-(2-trifluoromethylphenyl)-1H-[1,5]naphthyridin-2-one 
• 25797-03-9 2-phenyl-1H-pyrrolo[3,2-b]pyridine 
• 107468-56-4 methyl 3-((methoxycarbonyl)amino)picolinate 
• 824429-51-8 N-[2-(hydroxymethyl)pyridin-3-yl]carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS

The present invention provides a compound of Formula (I): (I) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).

PDE9 inhibitor and uses thereof

The invention belongs to the technical field of medicines, particularly relates to a PDE9 inhibitor compound shown as a formula (I) or pharmaceutically acceptable salt, isomer, a deuterated compound,metabolite and prodrug thereof, and further relates to pharmaceutical preparations, pharmaceutical compositions and application of the compounds. X1, X2, X3, X4, R1, R2, ring A, L and m are defined inthe specification. The compounds can be used for preparing medicines for treating or preventing related diseases mediated by PDE9.

Dual-Stage Picolinic Acid-Derived Inhibitors of Toxoplasma gondii

Toxoplasma gondii causes a prevalent human infection for which only the acute stage has an FDA-approved therapy. To find inhibitors of both the acute stage parasites and the persistent cyst stage that causes a chronic infection, we repurposed a compound library containing known inhibitors of parasitic hexokinase, the first step in the glycolysis pathway, along with a larger collection of new structural derivatives. The focused screen of 22 compounds showed a 77% hit rate (>50% multistage inhibition) and revealed a series of aminobenzamide-linked picolinic acids with submicromolar potency against both T. gondii parasite forms. Picolinic acid 23, designed from an antiparasitic benzamidobenzoic acid class with challenging ADME properties, showed 60-fold-enhanced solubility, a moderate LogD7.4, and a 30% improvement in microsomal stability. Furthermore, isotopically labeled glucose tracing revealed that picolinic acid 23 does not function by hexokinase inhibition. Thus, we report a new probe scaffold to interrogate dual-stage inhibition of T. gondii.

FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): wherein Ar is a the partial structure (1) to the partial structure (5), Q is a bivalent group selected from the group consisting of (Ia)-(If), and B is a ring optinally having substituent(s), or a salt thereof.

Azaindole synthesis through dual activation catalysis with N-heterocyclic carbenes

A convergent, transition-metal-free synthesis of 2-aryl-azaindoles has been developed. The interception of a reactive aza-ortho-azaquinone methide intermediate by an acyl anion equivalent generated through carbene catalysis provides high yields, a wide substrate scope, and the synthesis of previously inaccessible azaindoles.

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

Iminooxazolidine Derivatives and Their Use

The present application relates to novel iminooxazolidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.

FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R1 and R2 are each independently hydrogen, halogen, C1-8alkyl, -CN. or C1-8 haloalkyl, provided that at least one of R11or R2 is other than hydrogen; each R3 is independently hydrogen; R4 is hydrogen; R5 is halogen or C1-8 alkyl; R6 is hydrogen; X1 is CR7, N or NO; X2 and X4 are N or NO; X3 is CR7; X6 and X7 are each independently selected from CR7, N, and NO; each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C2-8 alkyl, substituted or unsubstituted C2-8 alkeπyl, substituted or unsubstituted C2-8 alkynyl, -CN. =O, -NO2, -OR6, -OC(O)R8, -CO2R8, -C(O)R8, -C(O)NR0R8, -OC(O)NR9R8, -NR10C(O)R8, -NR10C(O)NR9R8, -NR9R8, -NR10CO2R8, -SR8, -S(O)R8, -S(O)2R8, -S(O)2NR9R8, -NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;

HERBICIDAL COMPOUNDS

The present invention relates to a method of controlling plants or inhibiting plant growth which comprises applying to the plants or to the locus thereof a herbicidally effective amount of a compound of formula (I): wherein A1, A2, A3, A4, R3, R4 and R5 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to intermediates used in the preparation of compounds of formula (I), to herbicidal compositions comprising compounds of formula (I) and to certain novel pyridopyridines, pyridodiazines and pyridotriazines.